Zobrazeno 1 - 10
of 14
pro vyhledávání: ''
Publikováno v:
Anti-Cancer Drugs
Programmed cell death protein 1 (PD-1) inhibitors have demonstrated promising activity among patients with advanced soft tissue sarcomas (STS) in phase II trials. The purpose of this study was to assess the efficacy and safety of toripalimab (a novel
Autor:
Kazuhiko Nakagawa, Seiichiro Mitani, Shinichiro Suzuki, Takashi Kurosaki, Yasumasa Nishimura, Hidetoshi Hayashi, Soichi Fumita, Naoki Otsuki, Kazuki Ishikawa, Takeshi Yoshida, Katsumi Doi, Hiroaki Kanemura, Koji Haratani, Kaoru Tanaka, Mutsukazu Kitano, Tsutomu Iwasa
Publikováno v:
Anti-Cancer Drugs
Immunotherapy has been shown to prolong survival in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in front-line use; however, subsequent systemic therapy has not been optimized. This study aimed to evaluate the safety a
Autor:
Alberto D'Angelo, Pietro Rosellini, Michele Aieta, Giandomenico Roviello, Giorgio Chiriacò, Giovanni Paganini, Andrea Giovanni Multari, Silvia Paola Corona, Roberto Petrioli, Raffaele Conca
Publikováno v:
Roviello, G, Conca, R, D'Angelo, A, Multari, A G, Paganini, G, Chiriacò, G, Petrioli, R, Corona, S P, Rosellini, P & Aieta, M 2020, ' Association between neutropenia and response to ramucirumab and paclitaxel in patients with metastatic gastric cancer ', Anti-Cancer Drugs, vol. 31, no. 6, pp. 632-636 . https://doi.org/10.1097/CAD.0000000000000905
PURPOSE: The aim of this study was to evaluate if the occurrence of neutropenia is correlated with response to ramucirumab plus paclitaxel for metastatic gastric cancer.METHODS: This is a retrospective study of patients treated with ramucirumab plus
Autor:
Luigi Cerbone, Carlo Cattrini, Francesco Boccardo, Carlo Messina, Elisa Zanardi, Giacomo Vallome
Publikováno v:
Anti-cancer drugs. 30(8)
The phase III PROSELICA trial showed that cabazitaxel 20 mg/m (C20) was not inferior and better tolerated compared to cabazitaxel 25 mg/m (C25) in patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed during or afte
Autor:
Yan-Fang Huang, Xinli Wang, Xiaoyan Lin, Wan-Cai Que, Dongta Zhong, Ri-ping Wu, Yan-Qin Lan, Xiao-Bin Huang, Hong-Qiang Qiu, Bin Du, Xin-yan Gao
Publikováno v:
Anti-cancer drugs. 30(3)
The aim of this retrospective analysis was to evaluate the efficacy and toxicity of combination chemotherapy with paclitaxel, 5-fluorouracil, and leucovorin (TFL) as first-line treatment in patients with advanced gastric cancer (AGC). One hundred and
Autor:
Shengfa Su, Weiwei Ouyang, Yu Wang, Qingsong Li, Bing Lu, Zhu Ma, Wen-Gang Yang, Daxian Luo, ChaoFen Zhao, Ling-Feng Liu, Zhixu He, Yi-Chao Geng, Mei Li
Publikováno v:
Anti-cancer drugs. 30(3)
The aim of this study was to compare the clinical efficacy of pemetrexed+cisplatin (PP) versus docetaxel+cisplatin (DP) for the treatment of stage IV lung adenocarcinoma. We retrospectively analyzed the clinical data of 147 patients with stage IV lun
Autor:
Roberto Petrioli, Roberto Ponchietti, Letizia Laera, Anna Ida Fiaschi, Edoardo Francini, Giandomenico Roviello, Vincenzo Bianco
Publikováno v:
Anti-Cancer Drugs. 26:884-887
Both abiraterone acetate (AA) and cabazitaxel (Cbz) have been shown to prolong survival in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing during or after docetaxel (D). Although no standard sequencing has been estab
Publikováno v:
Anti-Cancer Drugs. 25:964-969
Febrile neutropenia is a complication of myleotoxic chemotherapy that can markedly decrease quality of life and increase healthcare costs. A granulocyte-colony stimulating factor (G-CSF) is used to increase neutrophil production to reduce the risk of
Autor:
Rut Isacson, Lior Mesika, Nathan I. Cherny, Tal Grenader, Norman Heching, Amiel Segal, Esther Tahover, Maya Gips, Alberto Gabizon, Ora Rosengarten, Raphael Catane
Publikováno v:
Anti-cancer drugs. 28(7)
Dexrazoxane is indicated as a cardioprotective agent for patients receiving doxorubicin who are at increased risk for cardiotoxicity. Concerns have been raised on the use of dexrazoxane, particularly in adjuvant therapy, because of the risk of interf
Autor:
Benjamin Linot, Anne-Lise Septans, Renaud Breheret, Olivier Capitain, Pauline Rives, Guillaume Peyraga, Sena Yossi, Dominique Rousseau, Laurent Laccourreye, Pierre Gustin
Publikováno v:
Anti-cancer drugs. 28(2)
Concurrent radiochemotherapy (CRC) is a standard treatment in patients with inoperable locoregionally advanced ear-nose-throat (ENT) cancer. We report the safety and efficacy of CRC with daily fractionated 5-fluorouracil and cisplatin ('F' 5FU-CDDP)